Clinical Trials Update from the American Heart Association Meeting: Ω-3 Fatty Acids and Arrhythmia Risk in Patients with an Implantable Defibrillator, ACTIV in CHF, VALIANT, the Hanover autologous bone marrow transplantation study, SPORTIF V, ORBIT and PAD and DEFINITE
Population
Patients with heart failure, post-MI patients with heart failure or major LV systolic dysfunction, patients…
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Trial summaries warrant cautious clinical use; leaves open optimal strategies for post-MI and arrhythmia management.
Key Points
- To summarize major clinical trial updates presented at the American Heart Association meeting regarding therapies for heart failure, arrhythmias, and myocardial dysfunction.
- Reviewed findings from multiple major clinical trials (ACTIV in CHF, VALIANT, Hanover study, SPORTIF V, ORBIT, PAD, DEFINITE, and omega-3 fatty acid trials).
- Evaluated outcomes across diverse therapeutic interventions including pharmacological agents, implantable devices, public access defibrillators, and stem cell transplantation.
- Omega-3 fatty acids showed a trend toward increased recurrence of ventricular arrhythmias without affecting mortality in patients with implantable defibrillators.
- VALIANT demonstrated that combined angiotensin receptor blockade and ACE inhibition reduced morbidity without lowering mortality in post-MI heart failure, while ACTIV in CHF supported arginine vasopressin antagonism.
- DEFINITE and public access defibrillation trials (ORBIT, PAD) confirmed life-saving benefits for defibrillators in non-ischemic cardiomyopathy and public settings, though both raised cost-effectiveness concerns.
Structured PICO
P
Population
Patients with heart failure, post-MI patients with heart failure or major LV systolic dysfunction, patients with non-ischemic cardiomyopathy, and patients with an implantable defibrillator
I
Intervention
Various interventions including Omega-3 fatty acids, arginine vasopressin antagonists, combination of angiotensin receptor antagonist and ACE inhibitor, autologous bone marrow cell transplantation, ximelagatran, public access defibrillators, and ICDs
This conference update highlights key trial results impacting heart failure and arrhythmia management, including pharmacological, device, and cell-based therapies.
Cite This Study
Cleland et al. (2004) studied this question.